News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The aim is to create new genomics solutions that could combat cancer and advance market access
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
The drug is indicated for mild and transient episodes of heart block
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
